Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Harrison Poulsbo Hematology and Onocology
mi
from
Poulsbo, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Updated: 1/1/1970
Harrison Poulsbo Hematology and Onocology
mi
from
Poulsbo, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Good Samaritan Cancer Center
mi
from
Puyallup, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Updated: 1/1/1970
Good Samaritan Cancer Center
mi
from
Puyallup, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
University of Washington; UW Medical Center
mi
from
Seattle, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Updated: 1/1/1970
University of Washington; UW Medical Center
mi
from
Seattle, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Minor and James Medical, PLLC
mi
from
Seattle, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Updated: 1/1/1970
Minor and James Medical, PLLC
mi
from
Seattle, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Group Health Capitol Hill Campus
mi
from
Seattle, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Updated: 1/1/1970
Group Health Capitol Hill Campus
mi
from
Seattle, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
University Cancer Center at University of Washington Medical Center
mi
from
Seattle, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Updated: 1/1/1970
University Cancer Center at University of Washington Medical Center
mi
from
Seattle, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Polyclinic First Hill
mi
from
Seattle, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Updated: 1/1/1970
Polyclinic First Hill
mi
from
Seattle, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Swedish Cancer Center
mi
from
Seattle, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Updated: 1/1/1970
Swedish Cancer Center
mi
from
Seattle, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Evergreen Hematology & Oncology
mi
from
Spokane, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Updated: 1/1/1970
Evergreen Hematology & Oncology
mi
from
Spokane, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Updated: 1/1/1970
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
St. Clare Hospital
mi
from
Tacoma, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Updated: 1/1/1970
St. Clare Hospital
mi
from
Tacoma, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
MultiCare Regional Cancer Center at Tacoma General Hospital
mi
from
Tacoma, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Updated: 1/1/1970
MultiCare Regional Cancer Center at Tacoma General Hospital
mi
from
Tacoma, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Allenmore Hospital
mi
from
Tacoma, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Updated: 1/1/1970
Allenmore Hospital
mi
from
Tacoma, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Northwest CCOP
mi
from
Tacoma, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Updated: 1/1/1970
Northwest CCOP
mi
from
Tacoma, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Franciscan Cancer Center at St. Joseph Medical Center
mi
from
Tacoma, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Updated: 1/1/1970
Franciscan Cancer Center at St. Joseph Medical Center
mi
from
Tacoma, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Southwest Washington Medical Center Cancer Center
mi
from
Vancouver, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Updated: 1/1/1970
Southwest Washington Medical Center Cancer Center
mi
from
Vancouver, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Updated: 1/1/1970
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Rocky Mountain Oncology
mi
from
Casper, WY
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Updated: 1/1/1970
Rocky Mountain Oncology
mi
from
Casper, WY
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Welch Cancer Center
mi
from
Sheridan, WY
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Central Lymphoma Repository Tissue Procurement Protocol
Status: Archived
Updated: 1/1/1970
Welch Cancer Center
mi
from
Sheridan, WY
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma: A Phase I Trial
Status: Archived
University of Kentucky Hospital
mi
from
Lexington, KY
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma: A Phase I Trial
Status: Archived
Updated: 1/1/1970
University of Kentucky Hospital
mi
from
Lexington, KY
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
An Observational Study of Plerixafor Mobilization Rescue for Autologous Stem Cell Transplant Patients With Inadequate Response to G-CSF
Status: Archived
Duke Univ Med Ctr
mi
from
Durham, NC
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
An Observational Study of Plerixafor Mobilization Rescue for Autologous Stem Cell Transplant Patients With Inadequate Response to G-CSF
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
mi
from
Durham, NC
Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
An Open-Label, Dose Escalation, Phase I Study of TAK-901 in Adult Patients With Advanced Solid Tumors or Lymphoma
Status: Archived
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
An Open-Label, Dose Escalation, Phase I Study of TAK-901 in Adult Patients With Advanced Solid Tumors or Lymphoma
Status: Archived
Updated: 1/1/1970
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
An Open-Label, Dose Escalation, Phase I Study of TAK-901 in Adult Patients With Advanced Solid Tumors or Lymphoma
Status: Archived
Karmanos Cancer Center
mi
from
Detroit, MI
Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
An Open-Label, Dose Escalation, Phase I Study of TAK-901 in Adult Patients With Advanced Solid Tumors or Lymphoma
Status: Archived
Updated: 1/1/1970
Karmanos Cancer Center
mi
from
Detroit, MI
Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
An Open-Label, Dose Escalation, Phase I Study of TAK-901 in Adult Patients With Advanced Solid Tumors or Lymphoma
Status: Archived
Fox Chase Cancer Center
mi
from
Philadephia, PA
Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
An Open-Label, Dose Escalation, Phase I Study of TAK-901 in Adult Patients With Advanced Solid Tumors or Lymphoma
Status: Archived
Updated: 1/1/1970
Fox Chase Cancer Center
mi
from
Philadephia, PA
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
A Phase I/II Study of Vaccination Against Minor Histocompatibility Antigens HA1 or HA2 After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
Status: Archived
University of Chicago
mi
from
Chicago, IL
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
A Phase I/II Study of Vaccination Against Minor Histocompatibility Antigens HA1 or HA2 After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
Status: Archived
Updated: 1/1/1970
University of Chicago
mi
from
Chicago, IL
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
A Phase I, Multicenter, Open-Label, Dose-Escalation, Multidose Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma or Relapsed/Refractory B-Cell Non Hodgkin's Lymphoma
Status: Archived
Yale University School of Medicine
mi
from
New Haven, CT
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
A Phase I, Multicenter, Open-Label, Dose-Escalation, Multidose Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma or Relapsed/Refractory B-Cell Non Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Yale University School of Medicine
mi
from
New Haven, CT
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
A Phase I, Multicenter, Open-Label, Dose-Escalation, Multidose Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma or Relapsed/Refractory B-Cell Non Hodgkin's Lymphoma
Status: Archived
Winship Cancer Institute of Emory University
mi
from
Egleston, GA
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
A Phase I, Multicenter, Open-Label, Dose-Escalation, Multidose Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma or Relapsed/Refractory B-Cell Non Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Winship Cancer Institute of Emory University
mi
from
Egleston, GA
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
A Phase I, Multicenter, Open-Label, Dose-Escalation, Multidose Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma or Relapsed/Refractory B-Cell Non Hodgkin's Lymphoma
Status: Archived
University of Chicago
mi
from
Chicago, IL
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
A Phase I, Multicenter, Open-Label, Dose-Escalation, Multidose Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma or Relapsed/Refractory B-Cell Non Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
University of Chicago
mi
from
Chicago, IL
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
A Phase I, Multicenter, Open-Label, Dose-Escalation, Multidose Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma or Relapsed/Refractory B-Cell Non Hodgkin's Lymphoma
Status: Archived
University of Maryland, Baltimore
mi
from
Baltimore, MD
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
A Phase I, Multicenter, Open-Label, Dose-Escalation, Multidose Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma or Relapsed/Refractory B-Cell Non Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
University of Maryland, Baltimore
mi
from
Baltimore, MD
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
A Phase I, Multicenter, Open-Label, Dose-Escalation, Multidose Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma or Relapsed/Refractory B-Cell Non Hodgkin's Lymphoma
Status: Archived
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
A Phase I, Multicenter, Open-Label, Dose-Escalation, Multidose Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma or Relapsed/Refractory B-Cell Non Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
University of Michigan Health Systems
mi
from
Ann Arbor, MI
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
University of Alabama - Burmingham
mi
from
Birmingham, AL
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
University of Alabama - Burmingham
mi
from
Birmingham, AL
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Alta Bates Summit Medical Center - Summit Campus
mi
from
Oakland, CA
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Alta Bates Summit Medical Center - Summit Campus
mi
from
Oakland, CA
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Scripps HealthCare
mi
from
LaJolla, CA
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Scripps HealthCare
mi
from
LaJolla, CA
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
University of Southern California Women's and Children's Hospital
mi
from
Los Angeles, CA
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
University of Southern California Women's and Children's Hospital
mi
from
Los Angeles, CA
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Sutter Cancer Center
mi
from
Sacramento, CA
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Sutter Cancer Center
mi
from
Sacramento, CA
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Rocky Mountain Cancer Center
mi
from
Denver, CO
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Rocky Mountain Cancer Center
mi
from
Denver, CO
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Emory University
mi
from
Atlanta, GA
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Emory University
mi
from
Atlanta, GA
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
University of North Carolina Hospital at Chapel Hill
mi
from
Chapel Hill, NC
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
University of North Carolina Hospital at Chapel Hill
mi
from
Chapel Hill, NC
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Sarah Cannon Cancer Center
mi
from
Nashville, TN
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Sarah Cannon Cancer Center
mi
from
Nashville, TN
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Baylor University Medical Center - Dallas
mi
from
Dallas, TX
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Baylor University Medical Center - Dallas
mi
from
Dallas, TX
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
VA South Texas Health Care System, San Antonio
mi
from
San Antonio, TX
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
VA South Texas Health Care System, San Antonio
mi
from
San Antonio, TX
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Texas Transplant Physician Group, PLLC
mi
from
San Antonio, TX
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Texas Transplant Physician Group, PLLC
mi
from
San Antonio, TX
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
Status: Archived
City of Hope Medical Canter
mi
from
Duarte, CA
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
Status: Archived
Updated: 1/1/1970
City of Hope Medical Canter
mi
from
Duarte, CA
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
Status: Archived
City of Hope Medical Group Inc
mi
from
Pasadena, CA
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
Status: Archived
Updated: 1/1/1970
City of Hope Medical Group Inc
mi
from
Pasadena, CA
Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma
Phase I/II of Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma
Phase I/II of Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1
Status: Archived
Barnes Jewish Hospital - Washington University
mi
from
St. Louis, MO
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1
Status: Archived
Updated: 1/1/1970
Barnes Jewish Hospital - Washington University
mi
from
St. Louis, MO